FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00077194 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: romidepsin

Sponsor

National Cancer Institute (NCI)